aap Implantate AG: Management Board and Supervisory Board plan share buyback to partially distribute proceeds from the sale of aap Biomaterials GmbH
In connection with the resolution on their proposals to the ordinary annual general meeting of the company Management Board and Supervisory Board of aap Implantate AG decided today to implement a share buyback within the next months in order to partially distribute proceeds from last year's sale of the subsidiary aap Biomaterials GmbH to shareholders as announced. Based on the current share price level of the aap share it is intended within the share buyback to purchase up to 2.4 million shares of the company from the shareholders for a maximum total purchase price (including incidental costs) of up to EUR 3.5 million. The further details of the share buyback, including the purchase price, will be determined and published by the Management Board with the consent of the Supervisory Board within the next weeks. If market circumstances or the share price development changes the Management Board reserves the right to adapt the conditions of the intended share buyback or refrain from it. Against the background of the intended share buyback Management Board and Supervisory Board will neither propose a dividend payment nor a capital decrease to the annual general meeting taking place on 16 June 2017 - both measures have been taken into consideration for the partial distribution of proceeds from the sale of aap Biomaterials GmbH as well. The proposals from Management Board and Supervisory Board to the annual general meeting will be published together with the convention on 10 May 2017 in the Federal Gazette. Contact: For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: email@example.com
_______________________________________________________________________________________aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -About aap Implantate AGaap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.Forward-looking statement This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
08-May-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: aap Implantate AG Lorenzweg 5 12099 Berlin
Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: firstname.lastname@example.org Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service
570793 08-May-2017 CET/CEST